Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use-Results Survey of ADLUMIZ in Cancer Cachexia
jRCT2011210014Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of adrecizumab in cancer anorexia-cachexia syndrome (CACS), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 2 more, sponsored by Ono Pharmaceutical. Primary endpoints: Safety - overall adverse drug reactions and infections, Safety - specified safety concerns and 3 more. Started Apr 2021; status: completed.
02
Drugs
adrecizumab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)gastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2011210014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210014.